Testing a new lung cancer drug after previous treatment stops working

Plain-English translation of NCT07155187 on ClinicalTrials.gov ↗ · Source last updated July 2026 · Translation generated July 2026 · How we translate trials

What is this trial?

This study is testing a new medication called to treat advanced lung cancer in people whose previous EGFR-targeting treatments have stopped working. The trial will test whether the medication works better when given alone or when combined with an existing drug called . About 490 people will participate across 200 hospitals and clinics worldwide over roughly 5.5 years.

When lung cancer with EGFR mutations comes back after the first-line treatments stop working, options become limited and the disease is harder to control. This trial aims to find out whether this new treatment can help people whose cancers have progressed despite previous therapy.

Do you qualify?

You likely qualify if…

you have been diagnosed with advanced or spread-out non-small cell lung cancer with specific EGFR mutations (Exon 19 deletion or Exon 21 L858R)
your cancer stopped responding to or got worse while on a third-generation EGFR-targeting drug
you have a recent or archived tumor sample available for testing
you are in generally good health with an ECOG performance status of 0 to 1 (able to carry out most daily activities)
your cancer has at least one measurable tumor that hasn't been treated with radiation

You likely don't qualify if…

you have a squamous cell type of lung cancer or adenosquamous lung cancer
you have received more than one line of chemotherapy or targeted therapy for advanced disease
you have active, untreated brain metastases (though previously treated and stable ones are okay)
you have a history of lung inflammation (interstitial lung disease or pneumonitis) that required steroid treatment
you have other serious medical conditions that your doctor believes would interfere with your participation

What participation looks like

You will receive the medication as an intravenous infusion at a hospital or clinic, with frequent visits for medical check-ups, blood tests, imaging scans, and questionnaires to monitor how well the treatment is working and check for side effects. The study will last about 5.5 years total, though the exact frequency of visits and duration of your personal involvement will depend on which treatment group you're assigned to and how you respond. Be prepared for more frequent visits and monitoring than you might receive with standard care outside of a clinical trial.

Testing a new lung cancer drug after previous treatment stops working

What is this trial?

Do you qualify?

What participation looks like

Trial locations(110 sites)